BGI-Shenzhen And Complete Genomics, Inc. Receive Early Termination Of Hart-Scott-Rodino Waiting Period

    BGI-Shenzhen And Complete Genomics, Inc. Receive Early Termination Of
                       Hart-Scott-Rodino Waiting Period

PR Newswire

SHENZHEN, China and MOUNTAIN VIEW, Calif., Jan. 7, 2013

SHENZHEN, China and MOUNTAIN VIEW, Calif., Jan. 7, 2013 /PRNewswire/
--BGI-Shenzhen ("BGI") and Complete Genomics, Inc. (Nasdaq: GNOM)
("Complete") announced today that they have received early termination of the
Hart-Scott-Rodino waiting period from the Federal Trade Commission ("FTC")
regarding BGI's proposed acquisition of Complete pursuant to the previously
announced Agreement and Plan of Merger, dated as of September 15, 2012, among
BGI, Beta Acquisition Corporation and Complete.

BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers
LLP. Complete's financial adviser is Jefferies & Company, and its legal
counsel is Latham & Watkins LLP.

Stockholders with questions about the Offer or who need assistance with
tendering their shares of common stock of Complete, may call the Information
Agent, Innisfree M&A Incorporated, toll-free, at (888) 750-5834.


Certain statements either contained in or incorporated by reference into this
document are forward-looking statements that involve risks and uncertainty.
Future events regarding the proposed transactions and both the BGI's and
Complete's actual results could differ materially from the forward-looking
statements. Factors that might cause such a difference include, but are not
limited to, statements regarding the combined companies' plans following, and
the expected completion of, the proposed acquisition. These forward-looking
statements involve certain risks and uncertainties that could cause actual
results to differ materially from those indicated in such forward-looking
statements and generally include statements that are predictive in nature and
depend upon or refer to future events or conditions. Risks and uncertainties
include the ability of BGI and Complete to complete the transactions
contemplated by the merger agreement, including the parties' abilities to
satisfy the conditions to the consummation of the proposed acquisition; the
possibility of any termination of the merger agreement; the timing of the
Offer and the subsequent merger; uncertainties as to how many of Complete's
stockholders will tender their shares of common stock in the Offer; the
possibility that various other conditions to the consummation of the Offer or
the subsequent merger may not be satisfied or waived, including that a
governmental entity may prohibit, delay or refuse to grant approval for the
consummation of the acquisition; other uncertainties pertaining to the
business of Complete or BGI; legislative and regulatory activity and
oversight; the continuing global economic uncertainty and other risks detailed
in Complete's public filings with the Securities and Exchange Commission (the
"SEC") from time to time, including Complete's most recent Annual Report on
Form 10-K for the year ended December 31, 2011, Quarterly Reports on Form 10-Q
and its subsequently filed SEC reports, each as filed with the SEC, which
contains and identifies important factors that could cause actual results to
differ materially from those contained in the forward-looking statements. The
reader is cautioned not to unduly rely on these forward-looking statements.
Each of Complete and BGI expressly disclaims any intent or obligation to
update or revise publicly these forward-looking statements except as required
by law.


This press release is neither an offer to purchase nor a solicitation of an
offer to sell shares of Complete. BGI and Beta Acquisition Corporation filed a
tender offer statement with the SEC on September 25, 2012, and mailed an offer
to purchase, forms of letter of transmittal and related documents to
Complete's stockholders. Complete filed a solicitation/recommendation
statement on Schedule14D-9 with the SEC on September 25, 2012, and mailed the
Schedule 14D-9 to Complete's stockholders . These documents, as they may be
amended from time to time, contain important information about the Offer and
stockholders of Complete are urged to read them carefully.

Investors may obtain a free copy of these documents and other relevant
documents filed with the SEC through the website maintained by the SEC at In addition, investors and stockholders will be able to obtain
free copies of these materials filed by Complete by contacting Investor
Relations by telephone at (650) 943-2788, by mail at Complete Genomics, Inc.,
Investor Relations, 2071 Stierlin Court, Mountain View, California 94043, or
by going to Complete's Investor Relations page on its corporate website at


 For BGI-Shenzhen:
In the U.S.:
 Jason Golz
 Brunswick Group
 Tel: (415) 671-7676

 In China:
 Elizabeth Liang
 Brunswick Group
 Tel: +852 3512 5000

Press spacebar to pause and continue. Press esc to stop.